Literature DB >> 3100885

Malignant B-cells have receptors for and respond to interleukin-2.

P Panayotides, R Lenkei, A Porwit, P Reizenstein.   

Abstract

Interleukin-2 (IL-2) for a long time has been considered as a T-cell specific growth factor which acts through distinct surface receptors present on activated, but not on resting, T-lymphocytes. Recently it has been shown that activated murine and human B-cells also express IL-2 receptors and respond to IL-2 with an increase of DNA synthesis. Some human B-cell malignancies have been reported to react with anti-IL-2 receptor antibodies, but no response to IL-2 has been documented in these cases. Here, in five of 11 B-cell leukemia/lymphoma cases, we identified cells which not only express the IL-2 receptor, but also respond to IL-2 stimulation, as shown by a marked increase of 3H-thymidine incorporation and by differentiation of lymphoma cells. The IL-2-induced 3H-thymidine uptake was completely blocked by a monoclonal antibody to IL-2 receptor, which indicates that IL-2 acted directly through functional IL-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3100885     DOI: 10.1007/bf02935002

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  27 in total

1.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

2.  Interleukin 2 regulates its own receptors.

Authors:  K A Smith; D A Cantrell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

3.  Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function.

Authors:  A Muraguchi; J H Kehrl; D L Longo; D J Volkman; K A Smith; A S Fauci
Journal:  J Exp Med       Date:  1985-01-01       Impact factor: 14.307

4.  Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2.

Authors:  P Ralph; G Jeong; K Welte; R Mertelsmann; H Rabin; L E Henderson; L M Souza; T C Boone; R J Robb
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

5.  Two distinct factors are required for induction of T-cell growth.

Authors:  E L Larsson; N N Iscove; A Coutinho
Journal:  Nature       Date:  1980-02-14       Impact factor: 49.962

6.  Stable expression of cDNA encoding the human interleukin 2 receptor in eukaryotic cells.

Authors:  W C Greene; R J Robb; P B Svetlik; C M Rusk; J M Depper; W J Leonard
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

7.  Human T cell leukemia/lymphoma virus I infection and subsequent cloning of normal human B cells. Direct responsiveness of cloned cells to recombinant interleukin 2 by differentiation in the absence of enhanced proliferation.

Authors:  S Tomita; J L Ambrus; D J Volkman; D L Longo; H Mitsuya; M S Reitz; A S Fauci
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

8.  Transient expression of interleukin 2 receptors. Consequences for T cell growth.

Authors:  D A Cantrell; K A Smith
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

9.  Expression of Tac antigen on activated normal human B cells.

Authors:  M Tsudo; T Uchiyama; H Uchino
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  3 in total

1.  Expression of p55 (Tac) interleukin-2 receptor (IL-2R), but not p75 IL-2R, in cultured H-RS cells and H-RS cells in tissues.

Authors:  S M Hsu; C K Tseng; P L Hsu
Journal:  Am J Pathol       Date:  1990-04       Impact factor: 4.307

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Development and characterization of a monoclonal antibody specific for the bovine low-affinity interleukin-2 receptor, BoCD25.

Authors:  B C Taylor; J L Stott; R J Scibienski; D Redelman
Journal:  Immunology       Date:  1992-09       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.